NCT00855205

Rituximab for Pulmonary Sarcoidosis

Rituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open-

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Cincinnati · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Sarcoidosis is a inflammatory disease affecting many parts of the body, especially the lungs. While most patients do well, there is a group of patients who require continuous doses of prednisone or other drugs. The current study will determine the role of Rituximab as new agent for patients with refractory disease.

Detailed description

Patients with refractory pulmonary sarcoidosis will be eligible for participation in this open label trial of Rituximab as additional therapy. The study will evaluate the efficacy of rituximab in improving the symptoms and functional capacity in patients with chronic sarcoidosis with pulmonary involvement who are symptomatic despite current treatment.

Conditions

• Sarcoidosis

Interventions

Type	Name	Description
DRUG	Rituximab	Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15

Timeline

• Start date: 2009-07-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2009-03-04
• Last updated: 2013-12-11

Locations

1 site across 1 country: United States